days they were divided into four portions (called specimens, thereafter) and transported to 1 a virological test facility where they were stored at -80°C. After thawing, the specimens 2 were used to infect Madin-Darby canine kidney (MDCK) cells. The cells were cultured for 7 3 days at 33°C, and the culture supernatants were used to test the susceptibility of the viral 4 neuraminidase to inhibition by laninamivir and oseltamivir carboxylate. A fluorometric 5 substrate, 4-methylumbelliferyl-N-acetyl-α-D-neuraminic acid, was used to measure the 6 50% inhibitory concentration (IC 50 ) of laninamivir and oseltamivir carboxylate (24). All 7 specimens of the H1N1 subtype obtained at the patient's first visit were tested for the 8 presence of the oseltamivir-resistant H274Y mutation (N2 numbering, the same as the 9 H275Y mutation by N1 numbering) by a reverse transcription polymerase chain reaction 10 (RT-PCR)/restriction fragment length polymorphism assay according to the procedure (3) 11 reported elsewhere. The serially diluted specimens infected MDCK cells, were cultured at 12 33°C for 7 days or until observation of a cytopathic effect in more than 75% of cells, and the 13 culture supernatants were recovered. The culture supernatants obtained were tested for the 14 presence of viruses by a hemaggultination assay with guinea pig red blood cells. The 15
Behrens-Kärber equation was used to calculate viral titers as log 10 tissue culture infective 16 dose (TCID 50 )/mL of the viral transport medium (1). A lower detection limit of the viral titer 17 was 1.5 TCID50/mL in the assay. The type and subtype of the influenza virus (H1N1, H3N2, 18 or B) was determined by performing RT-PCR with subtype-specific primers and viral RNA 19 extracted from the specimens or by the following serological test. Serum samples were 20 collected at Day 1 and Day 22 to perform a hemagglutination-inhibition assay. All virological 21 on June 16, 2017 by guest http://aac.asm.org/ Downloaded from tests were performed by Mitsubishi Chemical Medience Corporation (Tokyo, Japan). 1
Statistical analysis. 2
The sample size of 60 patients in each group was determined on the basis of the 3 previous randomized controlled trial (19) . Since the difference between the median time to 4 alleviation of influenza illness in the oseltamivir group and placebo group was 36 hours in 5 the previous trial, the sample size was determined to ensure that the upper limit of the 95% 6 confidence interval (CI) of the difference between each laninamivir dose level group and the 7 oseltamivir groups would be less than 36 hours with a probability of 80% based on the 8
Monte Carlo simulation. 9
In the efficacy analysis, we calculated the differences between the median time to 10 alleviation of influenza illness in each laninamivir dose level group and the oseltamivir 11 group (laninamivir−oseltamivir) and their two-sided non-parametric 95% CIs based on the 12 generalized Wilcoxon test. Generalized Wilcoxon tests were also performed for each 13 comparison between the treatment groups. The proportion of patients in each group who 14 were shedding virus at each time point was calculated. Viral titers <1.5 (the limit of 15 detection by the method used) were recorded as 1.5, and 1.5 was used to calculate the 16 median values. All analyses were performed using SAS ® System Release 8.2 software 17 (SAS Institute, Cary, NC). All reported P values are two-sided with no adjustments for 18 multiple testing. 19
The full analysis set (FAS) (5) based on the intention-to-treat principle was defined as the 20 on June 16, 2017 by guest http://aac.asm.org/ Downloaded from primary analysis set in the efficacy analysis, and the per protocol set (PPS) (5) was used in 1 the sensitivity analysis. The FAS included all randomized patients who met the major 2 eligibility criteria, had received at least 1 dose of the trial treatment, and had undergone at 3 least 1 assessment for influenza symptoms and axillary temperature. The PPS included all 4 patients who met the criteria for FAS and were sufficiently compliant with the protocol. 5
Results. 1
Patient disposition and characteristics. 2 A total of 186 patients were enrolled in the trial (FIG 1) . Of these, 2 patients discontinued 3 the trial before completing the first dose of the trial treatment and were excluded from the 4 FAS: one discontinued the trial before receiving treatment, and the other did not complete 5 inhalation. As a result, 184 patients (61, 61, and 62 in the laninamivir octanoate 40-mg 6 group, laninamivir octanoate 20-mg group, and oseltamivir group, respectively) were 7 included in the FAS. Of these, 1 patient in the 20-mg group received both laninamivir 8 octanoate and oseltamivir, and was analyzed as a member of the group to which the patient 9 was originally allocated. The 1 patient who discontinued the trial before treatment 10 (mentioned above) was excluded from the safety analysis. 11
The demographic and baseline characteristics of the 3 groups in the FAS were well 12 balanced (Table 1) Both dosages of laninamivir octanoate (20 mg and 40 mg) alleviated influenza illness 9 more rapidly than oseltamivir did (FIG 2) . The differences between the proportions of 10 patients whose illness was alleviated were apparent within 24 hours after the start of 11 treatment and persisted until 168 hours. In the FAS, the median time to alleviation of 12 influenza illness was significantly shorter in the laninamivir octanoate groups than in the 13 oseltamivir group, and the difference was of −31.9 hours in the 40-mg group and −31.0 14 hours in the 20-mg group (Table 2) . Similar results were also obtained in the PPS. 15
The subgroup analyses showed that both dosages of laninamivir octanoate markedly 16 reduced the median time to illness alleviation in the H1N1-infected subpopulation in 17 comparison with oseltamivir, and the difference was −60.9 hours in the 40-mg group and 18 −66.2 hours in the 20-mg group (Table 2) . Although the duration of clinical illness in the 19 patients with influenza A (H3N2) virus infection appeared to be shorter in the oseltamivir group than in the laninamivir octanoate groups, whereas among the 1 patients with influenza B virus infection, it appeared to be shorter in the laninamivir 2 octanoate groups than in the oseltamivir group, these differences were not 3 statistically significant.
4
Among the patients infected with influenza A (H1N1), the duration of fever was 5 significantly shorter in the laninamivir octanoate groups than in the oseltamivir group (Table  6 3). The duration of cough and the duration of rhinorrhea were also shorter in the laninamivir 7 octanoate groups, but the differences were statistically not significant (data not shown). 8
Viral shedding. 9
In the H1N1-infected subpopulation, the proportion of patients shedding virus at Day 6 10 was significantly lower in the laninamivir octanoate 20-mg group than in the oseltamivir 11 group (0% [0/40] and 25.0% [8/32], respectively, P<0.001)( Table 5 ). However, there were 12 no significant differences in median virus titers on Day 3 and 6 between laninamivir 13 octanoate groups and oseltamivir group. There were no statistically significant differences 14 between the laninamivir octanoate groups and oseltamivir group in the H3N2-infected 15 subpopulation or B-infected subpopulation (Table 5) . 16
Tolerability and safety. 17
Both drugs were well tolerated. The most common adverse events were gastrointestinal 18 events, including diarrhea, nausea, and vomiting. The event rates for diarrhea were 3.2% 19 octanoate 20-mg group, and oseltamivir group, respectively, for vomiting they were 3.2% 1 (2/62), 4.9% (3/61), and 6.5% (4/62), respectively, and for nausea they were 1.6% (1/62), 2 1.6% (1/61), and 0.0% (0/62), respectively. In addition, gastroenteritis was observed in 3 1.6% (1/62), 6.6% (4/61), and 3.2% (2/62) of the patients, respectively. These events were 4 generally mild to moderate and resolved within several days. Psychiatric disorders were 5 observed in 3 patients treated with laninamivir octanoate, and they consisted of abnormal 6 behavior in the 40-mg group and crying and delirium in the 20-mg group, but they were mild 7 and did not require any treatment. No clinically meaningful laboratory changes were 8 observed in any of the treatment groups. 9
Discussion. 10
In this trial, a single inhalation of laninamivir octanoate reduced the duration of influenza 11 illness by more than 30 hours in comparison with 10 doses of oseltamivir administered 12 orally over 5 days, mainly because most patients were infected with oseltamivir-resistant 13 seasonal influenza A (H1N1) with a H274Y (by N2 numbering) mutation. Accordingly, the 14 differences in duration of illness between the laninamivir octanoate groups and oseltamivir 15 group were marked in patients infected with influenza A (H1N1), that is, both dose levels of 16 laninamivir octanoate reduced the duration of illness by more than 60 hours in comparison 17 with oseltamivir. Thus, the results of this study demonstrated that laninamivir octanoate is 18 fully effective against oseltamivir-resistant seasonal influenza A (H1N1) strains clinically, 19 even though the effectiveness of oseltamivir against the H1N1 strain in children in the 20 1 oseltamivir groups also demonstrated greater efficacy of laninamivir octanoate against 2 oseltamivir-resistant influenza A (H1N1) virologically. The proportion of patients shedding 3 virus at Day 6 was significantly lower in the laninamivir octanoate 20-mg group than in the 4 oseltamivir group (Table 5) . However, there were no significant differences in median virus 5 titers between laninamivir groups and oseltamivir group, probably because the virus titers 6 on Day 1 were low (2.0-2.35) for unknown reasons. In addition, we assumed the virus titer 7 to be 1.5 if the virus titer was less than1.5. This approximation would affect the results. 8
There were no statistically significant differences in clinical efficacy between the 9 laninamivir octanoate groups and oseltamivir group against influenza A (H3N2) or B 10 infection mainly because the number of patients was small in this study. However, the 11 results of our previous study showed that oseltamivir is more effective clinically against 12 influenza A (H3N2) virus infection than against influenza A (H1N1) or B (16, 18) . 13
Both dosages of laninamivir octanoate (20 mg and 40 mg) were well tolerated. The 14 gastrointestinal adverse events were generally mild to moderate, and their rates were 15 similar in all 3 groups. A recent meta-analysis of randomized controlled trials showed that 16 diarrhea, vomiting, and nausea occurred in 6.6%, 6.7%, and 3.4%, respectively, of children 17 treated with placebo (14), findings that are comparable to our own. As the clinical effects 18
were similar in the 40-mg group and 20-mg group, and there was no statistically significant 19 difference in the virological effects between them, a higher dose is preferable for antiviral 20 therapy to prevent the emergence of drug-resistant variants.
The median time to illness alleviation did not differ significantly between the laninamivir 1 octanoate groups and oseltamivir group in the parallel trial in adult patients, although most 2 of the adult patients were infected with oseltamivir-resistant influenza A (H1N1). The 3 detailed analysis of the trial in adult patients will be reported elsewhere. Thus, there seems 4 to be a difference between the efficacy of laninamivir octanoate in adults and children. If 5 there actually is a difference in efficacy, we think that the difference in clinical response is 6 related to the patients' ages or to their immune status. Since the influenza illness in adults in 7 the parallel trial was mild, most adults may have recovered rapidly irrespective of whether 8 they were treated with laninamivir or oseltamivir or not treated at all. By contrast, the illness 9 caused by the same oseltamivir-resistant virus in the children in our trial may have been 10 severe enough to require treatment with a neuraminidase inhibitor. We previously reported 11 finding that oseltamivir was less effective against influenza B virus than against influenza A 12 virus in children (16), and in that study, we observed a phenomenon in which the 13 effectiveness of oseltamivir against influenza B increased with patient age. Therefore, the 14 adult patients treated with oseltamivir in the parallel trial may have recovered because they 15 were immune and not because oseltamivir was effective. 16
In conclusion, laninamivir octanoate was an effective and well-tolerated drug for the 17 treatment of children with oseltamivir-resistant influenza A (H1N1) virus infection. Age -yr Mean ± SD 6.8 ± 1.4 6.9 ± 1.5 6.7 ± 1.5 Range 3 -9 4 -9 3 -9 Sex -no. 
